BIGNUCOLO, ALESSIA
 Distribuzione geografica
Continente #
NA - Nord America 670
AS - Asia 242
EU - Europa 124
SA - Sud America 22
OC - Oceania 5
AF - Africa 3
Totale 1.066
Nazione #
US - Stati Uniti d'America 666
CN - Cina 105
SG - Singapore 98
IT - Italia 41
HK - Hong Kong 33
BR - Brasile 22
DE - Germania 21
FI - Finlandia 12
RU - Federazione Russa 11
PL - Polonia 10
FR - Francia 7
GB - Regno Unito 7
AU - Australia 5
CA - Canada 4
ES - Italia 3
UA - Ucraina 3
VN - Vietnam 3
ZA - Sudafrica 3
IE - Irlanda 2
IN - India 2
LT - Lituania 2
AT - Austria 1
BE - Belgio 1
HR - Croazia 1
NL - Olanda 1
SE - Svezia 1
TR - Turchia 1
Totale 1.066
Città #
Fairfield 107
Chandler 90
Singapore 58
Ashburn 42
Cambridge 40
Beijing 36
Seattle 36
Woodbridge 34
Santa Clara 32
Hong Kong 31
Houston 22
Boardman 21
Wilmington 21
Padova 16
Medford 15
Princeton 15
Des Moines 12
Helsinki 12
New York 12
Bytom 10
San Diego 9
Ann Arbor 8
Cagliari 6
Falkenstein 6
London 6
Philadelphia 6
Roxbury 6
Albignasego 5
Jinan 5
Melbourne 5
Los Angeles 4
Nanjing 4
Atglen 3
Madrid 3
Shanghai 3
Toronto 3
Council Bluffs 2
Dublin 2
Fuzhou 2
Hebei 2
Kharkiv 2
Kowloon 2
Munich 2
Norwalk 2
Nuremberg 2
Shenyang 2
Taizhou 2
Verona 2
Atlanta 1
Bagé 1
Barbacena 1
Belgorod 1
Borås 1
Brussels 1
Chicago 1
Coronel Domingos Soares 1
Curitiba 1
Dulles 1
Florianópolis 1
Francisco Beltrão 1
Genoa 1
Haikou 1
Hangzhou 1
Hanoi 1
Inhumas 1
Istanbul 1
Itaquaquecetuba 1
Jaboatão dos Guararapes 1
Jaú 1
Lençóis Paulista 1
Lutsk 1
Mogi Guaçu 1
Monte Carlo 1
Nanchang 1
Ogden 1
Olinda 1
Ottawa 1
Palmeira d'Oeste 1
Pimenta Bueno 1
Ribeirão Preto 1
Riese Pio X 1
Rio Claro 1
San Vito Al Tagliamento 1
Suzhou 1
São Paulo 1
Taiyuan 1
Tampa 1
Tucson 1
Ubaporanga 1
Utrecht 1
Viamão 1
Várzea da Palma 1
Zagreb 1
Totale 813
Nome #
FARMAPRICE: A Pharmacogenetic Clinical decision support system for precise and Cost-Effective Therapy 85
Genetic markers of the host to predict the efficacy of colorectal cancer targeted therapy 84
Pharmacogenomics of targeted agents for personalization of colorectal cancer treatment 81
PREEMPTIVE PHARMACOGENOMIC TESTING FOR PREVENTING ADVERSE DRUG REACTIONS (PREPARE): STATE OF ART AND PRELIMINARY RESULTS ON GENOTYPE ACTIONABILITY 78
Genetic biomarkers for hepatocellular cancer risk in a caucasian population. 72
Germline Polymorphisms in the Nuclear Receptors PXR and VDR as Novel Prognostic Markers in Metastatic Colorectal Cancer Patients Treated With FOLFIRI 69
Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-related gastrointestinal toxicity in metastatic colorectal cancer patients 66
The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice 65
Resveratrol in cancer patients: From bench to bedside 63
Il15ra and smad3 genetic variants predict overall survival in metastatic colorectal cancer patients treated with folfiri therapy: A new paradigm 55
Development of an Integrated Health IT Platform for a Precision Medicine Setting 52
Uso di marcatori farmacogenetici per migliorare la sicurezza e l'efficacia dei trattamenti antiblastici all'interno dello studio di implementazione delle linee guida PGx PREPARE 45
DEVELOPMENT OF AN INTEGRATED HEALTH IT PLATFORM FOR A PRECISE AND COST-EFFECTIVE THERAPY IN ONCOLOGY 44
SMAD3 Host and Tumor Profiling to Identify Locally Advanced Rectal Cancer Patients at High Risk of Poor Response to Neoadjuvant Chemoradiotherapy 40
Assessment of pharmacogenomic SLCO1B1 assay for prediction of neuromuscular pain in type 2 diabetes mellitus and cardiovascular patients: preliminary results 38
Integrative oncology: evidence-based medicine - The multidisciplinary experience of the Integrative Medicine Research Group (IMRG) 37
Sex disparities in efficacy in covid-19 vaccines: A systematic review and meta-analysis 33
The Multiple Effects of Vitamin D against Chronic Diseases: From Reduction of Lipid Peroxidation to Updated Evidence from Clinical Studies 28
Evaluation of Concomitant Use of Anticancer Drugs and Herbal Products: From Interactions to Synergic Activity 27
LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring 23
Totale 1.085
Categoria #
all - tutte 6.042
article - articoli 5.568
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.610


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202020 0 0 0 0 0 0 0 0 0 0 20 0
2020/2021106 11 1 26 1 19 3 3 0 26 3 4 9
2021/2022175 2 33 15 7 5 8 18 14 7 7 16 43
2022/2023173 28 20 1 18 29 27 0 14 18 1 16 1
2023/2024166 4 11 18 11 8 38 20 20 2 8 13 13
2024/2025333 3 30 14 25 59 25 31 52 23 29 42 0
Totale 1.085